tiprankstipranks
Replimune Group (REPL)
NASDAQ:REPL
US Market
REPL
Replimune Group
RESEARCH TOOLSreports
Want to see REPL full AI Analyst Report?

Replimune Group (REPL) Stock Forecast & Price Target

515 Followers
See the Price Targets and Ratings of:

REPL Analyst Ratings

Hold
8Ratings
Hold
0 Buy
6 Hold
2 Sell
Based on 8 analysts giving stock ratings to
Replimune
Group
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

REPL Stock 12 Month Forecast

Average Price Target

$4.20
▲(93.55% Upside)
Based on 8 Wall Street analysts offering 12 month price targets for Replimune Group in the last 3 months. The average price target is $4.20 with a high forecast of $8.00 and a low forecast of $1.00. The average price target represents a 93.55% change from the last price of $2.17.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","5":"$5","10":"$10","2.5":"$2.5","7.5":"$7.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$8.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4.2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$4.20</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$1.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,2.5,5,7.5,10],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2025","6":"Dec<br/>2025","9":"Mar<br/>2026","12":"Jun<br/>2026","25":"Jun<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9,8.923076923076923,8.846153846153847,8.76923076923077,8.692307692307692,8.615384615384615,8.538461538461538,8.461538461538462,8.384615384615385,8.307692307692308,8.23076923076923,8.153846153846153,8.076923076923077,{"y":8,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9,8.63076923076923,8.261538461538462,7.892307692307693,7.523076923076923,7.153846153846154,6.784615384615385,6.415384615384616,6.046153846153846,5.676923076923077,5.307692307692308,4.938461538461539,4.56923076923077,{"y":4.2,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9,8.384615384615385,7.769230769230769,7.153846153846153,6.538461538461538,5.923076923076923,5.3076923076923075,4.692307692307692,4.076923076923077,3.4615384615384617,2.846153846153846,2.23076923076923,1.615384615384615,{"y":1,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":9.57,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.15,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.6,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.9,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.21,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.73,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.71,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.72,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.975,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.16,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.61,"date":1775001600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":2.5,"date":1777593600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":9,"date":1780272000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$8.00Average Price Target$4.20Lowest Price Target$1.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
J.P. Morgan Analyst forecast on REPL
Anupam Rama
J.P. Morgan
J.P. Morgan
$8
Hold
268.66%
Upside
Upgraded
06/02/26
Analysts Offer Insights on Healthcare Companies: Replimune Group (NASDAQ: REPL), Eli Lilly & Co (NYSE: LLY) and Relay Therapeutics (NASDAQ: RLAY)
Leerink Partners Analyst forecast on REPL
Jonathan Chang
Leerink Partners
Leerink Partners
―
Hold
―
Reiterated
06/02/26
Analysts Offer Insights on Healthcare Companies: Astellas Pharma (Other OTC: ALPMF), AbbVie (NYSE: ABBV) and Replimune Group (NASDAQ: REPL)
Wedbush Analyst forecast on REPL
Robert Driscoll
Wedbush
Wedbush
$2→$6
Hold
176.50%
Upside
Assigned
06/01/26
Replimune price target raised to $6 from $2 at WedbushReplimune price target raised to $6 from $2 at Wedbush
H.C. Wainwright Analyst forecast on REPL
Robert Burns
H.C. Wainwright
H.C. Wainwright
―
Sell
―
Downgraded
04/13/26
Replimune downgraded to Sell from Buy at H.C. WainwrightReplimune downgraded to Sell from Buy at H.C. Wainwright
BMO Capital Analyst forecast on REPL
Evan Seigerman
BMO Capital
BMO Capital
$4.76→$1
Sell
-53.92%
Downside
Downgraded
04/13/26
Replimune downgraded to Underperform from Market Perform at BMO CapitalReplimune downgraded to Underperform from Market Perform at BMO Capital
Jefferies Analyst forecast on REPL
Roger Song
Jefferies
Jefferies
$13→$2
Hold
-7.83%
Downside
Downgraded
04/12/26
Replimune downgraded to Hold from Buy at JefferiesReplimune downgraded to Hold from Buy at Jefferies
Piper Sandler Analyst forecast on REPL
Allison Bratzel
Piper Sandler
Piper Sandler
$14→$4
Hold
84.33%
Upside
Downgraded
04/10/26
Replimune downgraded to Neutral from Overweight at Piper SandlerReplimune downgraded to Neutral from Overweight at Piper Sandler
Cantor Fitzgerald Analyst forecast on REPL
Li Watsek
Cantor Fitzgerald
Cantor Fitzgerald
―
Hold
―
Downgraded
04/10/26
Replimune downgraded to Neutral from Overweight at Cantor FitzgeraldReplimune downgraded to Neutral from Overweight at Cantor Fitzgerald
Barclays Analyst forecast on REPL
Peter Lawson
Barclays
Barclays
$3
Hold
38.25%
Upside
Reiterated
10/21/25
Barclays Keeps Their Hold Rating on Replimune Group (REPL)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
J.P. Morgan Analyst forecast on REPL
Anupam Rama
J.P. Morgan
J.P. Morgan
$8
Hold
268.66%
Upside
Upgraded
06/02/26
Analysts Offer Insights on Healthcare Companies: Replimune Group (NASDAQ: REPL), Eli Lilly & Co (NYSE: LLY) and Relay Therapeutics (NASDAQ: RLAY)
Leerink Partners Analyst forecast on REPL
Jonathan Chang
Leerink Partners
Leerink Partners
―
Hold
―
Reiterated
06/02/26
Analysts Offer Insights on Healthcare Companies: Astellas Pharma (Other OTC: ALPMF), AbbVie (NYSE: ABBV) and Replimune Group (NASDAQ: REPL)
Wedbush Analyst forecast on REPL
Robert Driscoll
Wedbush
Wedbush
$2→$6
Hold
176.50%
Upside
Assigned
06/01/26
Replimune price target raised to $6 from $2 at WedbushReplimune price target raised to $6 from $2 at Wedbush
H.C. Wainwright Analyst forecast on REPL
Robert Burns
H.C. Wainwright
H.C. Wainwright
―
Sell
―
Downgraded
04/13/26
Replimune downgraded to Sell from Buy at H.C. WainwrightReplimune downgraded to Sell from Buy at H.C. Wainwright
BMO Capital Analyst forecast on REPL
Evan Seigerman
BMO Capital
BMO Capital
$4.76→$1
Sell
-53.92%
Downside
Downgraded
04/13/26
Replimune downgraded to Underperform from Market Perform at BMO CapitalReplimune downgraded to Underperform from Market Perform at BMO Capital
Jefferies Analyst forecast on REPL
Roger Song
Jefferies
Jefferies
$13→$2
Hold
-7.83%
Downside
Downgraded
04/12/26
Replimune downgraded to Hold from Buy at JefferiesReplimune downgraded to Hold from Buy at Jefferies
Piper Sandler Analyst forecast on REPL
Allison Bratzel
Piper Sandler
Piper Sandler
$14→$4
Hold
84.33%
Upside
Downgraded
04/10/26
Replimune downgraded to Neutral from Overweight at Piper SandlerReplimune downgraded to Neutral from Overweight at Piper Sandler
Cantor Fitzgerald Analyst forecast on REPL
Li Watsek
Cantor Fitzgerald
Cantor Fitzgerald
―
Hold
―
Downgraded
04/10/26
Replimune downgraded to Neutral from Overweight at Cantor FitzgeraldReplimune downgraded to Neutral from Overweight at Cantor Fitzgerald
Barclays Analyst forecast on REPL
Peter Lawson
Barclays
Barclays
$3
Hold
38.25%
Upside
Reiterated
10/21/25
Barclays Keeps Their Hold Rating on Replimune Group (REPL)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Replimune Group

3 Months
Evan SeigermanBMO Capital
Success Rate
10/24 ratings generated profit
42%
Average Return
-27.04%
Copying Evan Seigerman's trades and holding each position for 3 Months would result in 41.67% of your transactions generating a profit, with an average return of -27.04% per trade.
1 Year
Evan SeigermanBMO Capital
Success Rate
8/24 ratings generated profit
33%
Average Return
-45.95%
Copying Evan Seigerman's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of -45.95% per trade.
2 Years
Evan SeigermanBMO Capital
Success Rate
1/24 ratings generated profit
4%
Average Return
-75.15%
Copying Evan Seigerman's trades and holding each position for 2 Years would result in 4.17% of your transactions generating a profit, with an average return of -75.15% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

REPL Analyst Recommendation Trends

Rating
Feb 26
Mar 26
Apr 26
May 26
Jun 26
Strong Buy
1
1
1
0
0
Buy
0
0
0
0
0
Hold
2
3
6
6
8
Sell
0
0
3
3
3
Strong Sell
0
0
0
0
0
total
3
4
10
9
11
In the current month, REPL has received 0 Buy Ratings, 8 Hold Ratings, and 3 Sell Ratings. REPL average Analyst price target in the past 3 months is 4.20.
Each month's total comprises the sum of three months' worth of ratings.

REPL Financial Forecast

REPL Earnings Forecast

Currently, no earnings data available.
Currently, no earnings data available.
No data currently available

REPL Sales Forecast

Currently, no sales data available.
Currently, no sales data available.

REPL Stock Forecast FAQ

What is REPL’s average 12-month price target, according to analysts?
Based on analyst ratings, Replimune Group’s 12-month average price target is 4.20.
    What is REPL’s upside potential, based on the analysts’ average price target?
    Replimune Group has 93.55% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is REPL a Buy, Sell or Hold?
          Replimune Group has a consensus rating of Hold which is based on 0 buy ratings, 6 hold ratings and 2 sell ratings.
            What is Replimune Group’s price target?
            The average price target for Replimune Group is 4.20. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $8.00 ,the lowest forecast is $1.00. The average price target represents 93.55% Increase from the current price of $2.17.
              What do analysts say about Replimune Group?
              Replimune Group’s analyst rating consensus is a Hold. This is based on the ratings of 8 Wall Streets Analysts.
                How can I buy shares of REPL?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.